By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- A new study on Lymphoproliferative Disorders is now available. According to news originating from Aachen, Germany, by NewsRx correspondents, research stated, "Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL) are rare lymphoproliferative cancer types. Although most HL patients can be cured by chemo- and radio-therapy, 4-50% of patients relapse and have a poor prognosis."
Our news journalists obtained a quote from the research from Institute for Molecular Biotechnology, "The need for improved therapeutic options for patients with relapsed or refractory disease has been addressed by CD30-specific antibody-based immunotherapeutics. However, available CD30-specific monoclonal antibodies (mAbs), antibody drug conjugates (ADCs) or chimeric immunotoxins suffer from the requirement of a functional host immunity, undesirable immune reactions or heterogeneity and instability, respectively. Here, we present a new fusion protein comprised of the CD30-specific antibody single-chain fragment Ki4(scFv) and the human pro-apoptotic effector protein, microtubule-associated protein tau (MAPT). Ki4(scFv)-MAP selectively induced apoptosis in rapidly proliferating L540cy, L428, and Karpas 299 cells in a dose-dependent manner. Tubulin polymerization assays confirmed that Ki4(scFv)-MAP stabilizes microtubules, suggesting a mechanism for its pro-apoptotic action. Dose-finding experiments proved that Ki4(scFv)-MAP is well tolerated in mice compared to the previously reported Ki4(scFv)-ETA'. Ki4(scFv)-MAP significantly inhibited growth of subcutaneous L540cy xenograft tumours in mice."
According to the news editors, the research concluded: "Our data present a novel approach for the treatment of CD30(+) lymphomas, combining the binding specificity of a target-specific antibody fragment with the selective cytotoxicity of MAPT towards proliferating lymphoma cells."
For more information on this research see: Human microtubule-associated protein tau mediates targeted killing of CD30(+) lymphoma cells in vitro and inhibits tumour growth in vivo. British Journal of Haematology, 2014;164(2):251-257. British Journal of Haematology can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - www.wiley.com/; British Journal of Haematology - onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2141)
The news correspondents report that additional information may be obtained from D. Hristodorov, Rhein Westfal TH Aachen, Inst Mol Biotechnol Biol 7, Aachen, Germany. Additional authors for this research include J. Nordlohne, R. Mladenov, M. Huhn, R. Fischer, T. Thepen and S. Barth (see also Lymphoproliferative Disorders).
Keywords for this news article include: Antibodies, Aachen, Europe, Germany, Oncology, Cytoplasm, Hematology, Immunology, Cytoskeleton, Therapeutics, Blood Proteins, Immunoglobulins, Lymphatic Diseases, Cellular Structures, Intracellular Space, Microtubule Proteins, Lymphoma Gene Therapy, Nerve Tissue Proteins, Immunoproliferative Disorders
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC